Last reviewed · How we verify
NCT04663035
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
Status unknown
Phase 2
Last updated 22 March 2023
What this trial tests
Phase 2 trial testing Tislelizumab in Recurrent Hepatocellular Carcinoma in 120 participants. Status unknown.
Timeline
21 December 2020
Primary endpoint
18 December 2023
18 December 2023
18 December 2025
Quick facts
| Lead sponsor | Ming Zhao |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 21 December 2020 |
| Primary completion | 18 December 2023 |
| Estimated completion | 18 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tislelizumab (TISLELIZUMAB) — full drug profile →
- Ablation
Conditions studied
- Recurrent Hepatocellular Carcinoma — all drugs for Recurrent Hepatocellular Carcinoma →
Sponsor
Ming Zhao — full company profile →
Who can join
18 and older, any sex, with Recurrent Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311 -
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).
Bicer F, Kure C, Ozluk AA, El-Rayes BF, et al · · 2023 · cited 30× · PMID 37999131 · DOI 10.3390/curroncol30110711 -
Current status and prospect of treatments for recurrent hepatocellular carcinoma.
Yang YQ, Wen ZY, Liu XY, Ma ZH, et al · · 2023 · cited 18× · PMID 36926237 · DOI 10.4254/wjh.v15.i2.129 -
Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.
Hatzidakis A, Müller L, Krokidis M, Kloeckner R. · · 2022 · cited 17× · PMID 35626073 · DOI 10.3390/cancers14102469 -
Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. · · 2022 · cited 13× · PMID 35949435 · DOI 10.5306/wjco.v13.i6.448 -
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.
Eghbali S, Heumann TR. · · 2025 · cited 11× · PMID 39858016 · DOI 10.3390/cancers17020236 -
Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma.
Liang J, Bai Y, Ha FS, Luo Y, et al · · 2023 · cited 11× · PMID 36684055 · DOI 10.4251/wjgo.v15.i1.1 -
Contribution of immune cells in synergistic anti-tumor effect of ablation and immunotherapy.
He N, Jiang J. · · 2024 · cited 8× · PMID 38070356 · DOI 10.1016/j.tranon.2023.101859
Verify or expand the search:
- PubMed search for NCT04663035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tislelizumab
Trials testing the same drug.
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
- NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
Other recruiting trials for Recurrent Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06609850 — The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma · NA · recruiting
- NCT05103904 — Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant · Phase 2 · recruiting
- NCT04514484 — Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and · Phase 1 · active not recruiting
- NCT04851119 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors · Phase 1, PHASE2 · recruiting
- NCT04615143 — Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC · Phase 2 · recruiting
Other Ming Zhao trials
Trials by the same sponsor.
- NCT02436044 — HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC · approved for marketing
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04663035 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ming Zhao
- Last refreshed: 22 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04663035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing